Cytek Biosciences Inc (NAS:CTKB)

Q4 2025 Cytek Biosciences Inc Earnings Call Transcript

Feb 26, 2026 / 09:30 PM GMT

Release Date Price: $4.4 (+0.69%)

Transcript 10-K8-K

Key Points

Positve

Cytek Biosciences Inc (CTKB) achieved a record high quarterly revenue of $62.1 million in Q4 2025, marking an 8% year-over-year increase.
The company saw strong geographic performance with double-digit revenue growth in both the EMEA and APAC regions.
Recurring revenue grew significantly, representing 34% of total revenue and increasing by 21% year-over-year.
The launch of the Aurora Evo system contributed to a 21% unit growth in the Aurora category in Q4 2025.
Cytek Biosciences Inc (CTKB) expanded its global footprint by adding 208 instruments, bringing the total installed base to 3,664 units.

Negative

GAAP gross profit margin declined to 53% in Q4 2025 from 59% in the prior year quarter, due to increased headcount, travel costs, and higher manufacturing overhead.
The company reported a net loss of $44.1 million in Q4 2025, largely due to a $38.1 million valuation allowance against deferred tax assets.
Operating expenses increased by 25% in Q4 2025 compared to the previous year, driven by higher general and administrative costs.
Product revenue growth was modest at 3% in Q4 2025, with flat instrument revenue in the US due to weaker demand from biotech and pharma sectors.
Adjusted EBITDA declined to $4.5 million in Q4 2025 from $12.5 million in the prior year quarter, primarily due to higher operating expenses and lower gross profit.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CTKB.OQ - Cytek Biosciences Inc
Q4 2025 Cytek Biosciences Inc Earnings Call
Feb 26, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Tina and I will be your conference operator today. At this time, I would like to welcome everyone to the Scitech of Science's 4th quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question-and-answer session. To ask a question, simply press 1 on your telephone keypad. To withdraw your question, press 1 again. It is now my pleasure to turn the call over to Paul Goodson, head of investor relations. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.